Lactic acid bacteria for delivery of endogenous or engineered therapeutic molecules

Frontiers in Microbiology

Volumn 9, Issue AUG, 2018, Pages

  Bron, Peter A ^a,b   Kleerebezem, Michiel ^b,c  

^a NIZO FOOD RESEARCH   (Netherlands)

^b BE Basic Foundation   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Genetic engineering; Lactic acid bacteria; Lactobacillus; Lactococcus lactis; Probiotics; Therapeutic molecules

Indexed keywords

ANTIINFECTIVE AGENT; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 4; LYSOSTAPHIN; PROBIOTIC AGENT; PROTEIN KINASE B;

DIABETIC FOOT; FERMENTED PRODUCT; GENE EXPRESSION; GENETIC ENGINEERING; HEALTHY DIET; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE MUCOSA; LACTIC ACID BACTERIUM; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SIMULANS;

EID: 85051080506     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.01821     Document Type: Review

References (32)

1. Bauerl, C., Perez-Martinez, G., Yan, F., Polk, D. B., and Monedero, V. (2010). Functional analysis of the p40 and p75 proteins from Lactobacillus casei BL23. J. Mol. Microbiol. Biotechnol. 19, 231-241. doi: 10.1159/000322233
2. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J. P., et al. (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759. doi: 10.1016/j.cgh.2006.03.028
3. Bron, P. A., Tomita, S., Mercenier, A., and Kleerebezem, M. (2013). Cell surface-associated compounds of probiotic lactobacilli sustain the strain-specificity dogma. Curr. Opin. Microbiol. 16, 262-269. doi: 10.1016/j.mib.2013.06.001
4. Bron, P. A., van Baarlen, P., and Kleerebezem, M. (2011). Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 10, 66-78. doi: 10.1038/nrmicro2690
5. Duar, R. M., Lin, X. B., Zheng, J., Martino, M. E., Grenier, T., Perez-Munoz, M. E., et al. (2017). Lifestyles in transition: evolution and natural history of the genus Lactobacillus. FEMS Microbiol. Rev. 41, S27-S48. doi: 10.1093/femsre/fux030
6. Fernandez-Gutierrez, M. M., Roosjen, P. P. J., Ultee, E., Agelink, M., Vervoort, J. J. M., Keijser, B., et al. (2017). Streptococcus salivarius MS-oral-D6 promotes gingival re-epithelialization in vitro through a secreted serine protease. Sci. Rep. 7:11100. doi: 10.1038/s41598-017-11446-z
7. Frossard, C. P., Steidler, L., and Eigenmann, P. A. (2007). Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin. Immunol. 119, 952-959. doi: 10.1016/j.jaci.2006.12.615
8. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506-514. doi: 10.1038/nrgastro.2014.66
9. Hume, D. A., and MacDonald, K. P. (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810-1820. doi: 10.1182/blood-2011-09-379214
10. Klaenhammer, T. R., Kleerebezem, M., Kopp, M. V., and Rescigno, M. (2012). The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol. 12, 728-734. doi: 10.1038/nri3312
11. Kok, J., van Gijtenbeek, L. A., de Jong, A., van der Meulen, S. B., Solopova, A., and Kuipers, O. P. (2017). The evolution of gene regulation research in Lactococcus lactis. FEMS Microbiol. Rev. 41, S220-S243. doi: 10.1093/femsre/fux028
12. Lebeer, S., Bron, P. A., Marco, M. L., Van Pijkeren, J. P., O'Connell Motherway, M., Hill, C., et al. (2018). Identification of probiotic effector molecules: present state and future perspectives. Curr. Opin. Biotechnol. 49, 217-223. doi: 10.1016/j.copbio.2017.10.007
13. Li, R., Zhang, Y., Polk, D. B., Tomasula, P. M., Yan, F., and Liu, L. (2016). Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system. J. Control. Release 230, 79-87. doi: 10.1016/j.jconrel.2016.04.009
14. McLean, M. H., Andrews, C., Hanson, M. L., Baseler, W. A., Anver, M. R., Senkevitch, E., et al. (2017). Interleukin-27 Is a potential rescue therapy for acute severe colitis through interleukin-10-dependent. Inflamm. Bowel Dis. 23, 1983-1995. doi: 10.1097/MIB.0000000000001274
15. Mierau, I., and Kleerebezem, M. (2005). 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 68, 705-717. doi: 10.1007/s00253-005-0107-6
16. Mierau, I., Leij, P., van Swam, I., Blommestein, B., Floris, E., Mond, J., et al. (2005). Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin. Microb. cell fact. 4:15
17. Mohammedsaeed, W., Cruickshank, S., McBain, A. J., and O'Neill, C. A. (2015). Lactobacillus rhamnosus GG lysate increases re-epithelialization of keratinocyte scratch assays by promoting migration. Sci. Rep. 5:16147. doi: 10.1038/srep16147
18. Quickel, K. E. Jr., Selden, R., Caldwell, J. R., Nora, N. F., and Schaffner, W. (1971). Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl. Microbiol. 22, 446-450
19. Robert, S., Gysemans, C., Takiishi, T., Korf, H., Spagnuolo, I., Sebastiani, G., et al. (2014). Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63, 2876-2887. doi: 10.2337/db13-1236
20. Robert, S., and Steidler, L. (2014). Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 diabetes case. Microb. cell fact. 13(Suppl. 1):S11. doi: 10.1186/1475-2859-13-S1-S11
21. Sica, A., and Mantovani, A. (2012). Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795. doi: 10.1172/JCI59643
22. Steidler, L. (2003). Genetically engineered probiotics. Best pract. Res. Clin. Gastroenterol. 17, 861-876. doi: 10.1016/S1521-6918(03)00072-6
23. Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., et al. (2000). Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355. doi: 10.1126/science.289.5483.1352
24. Szatraj, K., Szczepankowska, A. K., and Chmielewska-Jeznach, M. (2017). Lactic acid bacteria-promising vaccine vectors: possibilities, limitations, doubts. J. Appl. Microbiol. 123, 325-339. doi: 10.1111/jam.13446
25. Thumm, G., and Gotz, F. (1997). Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol. Microbiol. 23, 1251-1265. doi: 10.1046/j.1365-2958.1997.2911657.x
26. van Baarlen, P., Troost, F., van der Meer, C., Hooiveld, G., Boekschoten, M., Brummer, R. J., et al. (2011). Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4562-4569. doi: 10.1073/pnas.1000079107
27. Vandenbroucke, K., Hans, W., Van Huysse, J., Neirynck, S., Demetter, P., Remaut, E., et al. (2004). Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127, 502-513. doi: 10.1053/j.gastro.2004.05.020
28. Wang, M., Gao, Z., Zhang, Y., and Pan, L. (2016). Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl. Microbiol. Biotechnol. 100, 5691-5701. doi: 10.1007/s00253-016-7557-x
29. Wyszynska, A., Kobierecka, P., Bardowski, J., and Jagusztyn-Krynicka, E. K. (2015). Lactic acid bacteria-20 years exploring their potential as live vectors for mucosal vaccination. Appl. Microbiol. Biotechnol. 99, 2967-2977. doi: 10.1007/s00253-015-6498-0
30. Yan, F., Cao, H., Cover, T. L., Washington, M. K., Shi, Y., Liu, L., et al. (2011). Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121, 2242-2253. doi: 10.1172/JCI44031
31. Yan, F., and Polk, D. B. (2012). Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut microbes 3, 25-28. doi: 10.4161/gmic.19245
32. Yun, Y. R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., et al. (2010). Fibroblast growth factors: biology, function, and application for tissue regeneration. J. Tissue Eng. 2010:218142. doi: 10.4061/2010/218142